Q4 2024. Management View. CEO Kristin Peck highlighted Zoetis delivered an excellent 2024, achieving double-digit operational revenu ...

Simparica Trio Revenue: Exceeded $1 billion globally ... Share Repurchase: $1.9 billion of Zoetis shares repurchased in 2024.

Q4 2024 Earnings Call Transcript February 13, 2025 Zoetis Inc. beats earnings expectations. Reported EPS is $1.4, ...

ZTS delivered fourth-quarter 2024 adjusted earnings (excluding one-time items) of $1.40 per share, which surpassed the Zacks ...

Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...

Coming up: In 2025, Zoetis is set to face more direct competition for some its flagship therapies, including Apoquel and Simparica Trio. It's not clear that rival Elanco's new entrants (Zenrelia ...

During the fourth quarter, Zoetis observed major revenue growth in companion animal products, marking an 8% increase. This growth is attributed to notable products such as Simparica Trio ...

Elanco is only now close to rolling out Zenrelia and Credelio Quattro, while Zoetis’ comparable products Apoquel and Simparica Trio enjoyed headstarts of 10 and four years, respectively.

ZTS' higher companion animal product sales are likely to have driven revenues in fourth-quarter 2024 in both the United ...